Spirit Airlines Reverses Pilot Furlough Plans Amid Updated Staffing Outlook 
Proxy Advisors Urge Vote Against ANZ’s Executive Pay Report Amid Scandal Fallout 
Tesla Expands Affordable Model 3 Lineup in Europe to Boost EV Demand 
Lockheed Martin Secures $1.14 Billion Contract Boost for F-35 Production 
Netflix’s $72 Billion Warner Bros Discovery Deal Reshapes the Entertainment Landscape 
Firelight Launches as First XRP Staking Platform on Flare, Introduces DeFi Cover Feature 
Allegiant Air Faces Union Block in Bid for Foreign Pilots’ Green Cards Amid Staffing Challenges 
OpenAI Moves to Acquire Neptune as It Expands AI Training Capabilities 
Amazon Italy Pays €180M in Compensation as Delivery Staff Probe Ends 
Visa to Move European Headquarters to London’s Canary Wharf 
Hikvision Challenges FCC Rule Tightening Restrictions on Chinese Telecom Equipment 
Australia Moves Forward With Teen Social Media Ban as Platforms Begin Lockouts 
SpaceX CEO Elon Musk Denies Reports of $800 Billion Valuation Fundraise 
U.S.-EU Tensions Rise After $140 Million Fine on Elon Musk’s X Platform 
Boeing Executive Says Trump’s Equity Stake Plan Won’t Target Major Defense Contractors 
Southwest Airlines Has $11 Million Fine Waived as USDOT Cites Operational Improvements 
EU Prepares Antitrust Probe Into Meta’s AI Integration on WhatsApp 
Illumina, Inc., a leader in DNA sequencing and array technologies, has launched a pilot proteomics program analyzing 50,000 UK Biobank samples. In collaboration with deCODE Genetics, GSK, Novartis, and others, the initiative utilizes Illumina’s next-gen proteomics assay, Protein Prep™, powered by SOMAmer® technology. This solution promises scalable access to proteomic insights, enabling advancements in drug discovery and disease research.
Proteomics, which examines protein functions and biomarkers, supports breakthroughs in cancer, cardiovascular disease, and other conditions. Illumina’s high-throughput Protein Prep technology enhances protein quantitative trait loci (pQTL) discovery, linking genetic variations to protein expression and disease phenotypes.
UK Biobank will contribute 50,000 samples, including 30,000 funded by Illumina, deCODE Genetics, and Standard BioTools. The samples will be processed using NovaSeq™ X Plus and the DRAGEN Protein Quantification pipeline. Data from these samples will be shared with researchers in 2025. For the remaining 20,000 samples, consortium members will receive exclusive access before release to the broader scientific community.
Illumina aims to deliver rich proteomics data to accelerate medical research. “This project will generate high-quality data, advancing biological insights for researchers and pharma partners,” said Steve Barnard, CTO of Illumina.
UK Biobank Principal Investigator Sir Rory Collins praised the program’s potential to enhance understanding of genetics, environment, and lifestyle in disease development. Standard BioTools CEO Michael Egholm highlighted the transformative potential of combining SOMAmer multiplexing with next-gen sequencing.
The Illumina Protein Prep assay detects 9,000 proteins using 11,000 SOMAmer reagents and supports multiomics studies on NovaSeq platforms. Full launch is expected in early 2025.
This pilot marks a milestone in proteomics, fostering collaboration between researchers and industry leaders to advance global healthcare.
